Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
grade F 17.27 -2.81% -0.50
NKTR closed down 2.81 percent on Friday, October 18, 2019, on 1.13 times normal volume.

Earnings due: Nov 5

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical NKTR trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -2.81%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.81%
Narrow Range Bar Range Contraction -2.81%
NR7 Range Contraction -2.81%
Up 3 Days in a Row Strength -2.81%
Slingshot Bearish Bearish Swing Setup -1.54%
MACD Bullish Signal Line Cross Bullish -1.54%
Slingshot Bearish Bearish Swing Setup -0.14%
Bullish Engulfing Bullish -0.14%

Older signals for NKTR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.
Chemistry Biotechnology Biopharmaceutical Manufacturing Pharmaceutical Pain Drugs Pharmacology Ovarian Cancer Chronic Pain Morphinans Anti Infectives Metastatic Breast Cancer Opioid Antagonists Pegylation Treatment Of Metastatic Breast Cancer Diols Metastatic Colorectal Cancer Opioid Induced Constipation
Is NKTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 18 FINAL DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019
Oct 16 FINAL DEADLINE APPROACHING: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics
Oct 16 Nektar launches early-stage study of NKTR-255 in blood cancer
Oct 16 NKTR CLASS ACTION DEADLINE IN 1 DAY: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Nektar Therapeutics
Oct 16 Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
Oct 16 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm
Oct 15 INVESTOR DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics
Oct 12 Does Nektar Therapeutics (NASDAQ:NKTR) Have A Healthy Balance Sheet?
Oct 12 CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Approaching Deadlines Related to the Following Companies: VAL, NKTR and NTAP
See more NKTR news...
Indicator Value
52 Week High 48.44
52 Week Low 15.635
Average Volume 4,345,130
200-Day Moving Average 31.2927
50-Day Moving Average 18.184
20-Day Moving Average 17.738
10-Day Moving Average 17.0525
Average True Range 1.1149
ADX 30.07
+DI 16.6456
-DI 30.455
Chandelier Exit (Long, 3 ATRs ) 17.4153
Chandelier Exit (Short, 3 ATRs ) 18.9797
Upper Bollinger Band 19.7993
Lower Bollinger Band 15.6767
Percent B (%b) 0.39
BandWidth 23.241628
MACD Line -0.6737
MACD Signal Line -0.7789
MACD Histogram 0.1052
Fundamentals Value
Market Cap 2.7 Billion
Num Shares 156 Million
EPS -1.40
Price-to-Earnings (P/E) Ratio -12.34
Price-to-Sales 27.79
Price-to-Book 1075.45
PEG Ratio 3.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.98
Resistance 3 (R3) 18.99 18.44 18.70
Resistance 2 (R2) 18.44 18.00 18.43 18.60
Resistance 1 (R1) 17.85 17.73 17.58 17.84 18.50
Pivot Point 17.30 17.30 17.16 17.29 17.30
Support 1 (S1) 16.71 16.86 16.44 16.70 16.04
Support 2 (S2) 16.16 16.59 16.15 15.94
Support 3 (S3) 15.57 16.16 15.85
Support 4 (S4) 15.56